Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
2019; Massachusetts Medical Society; Volume: 381; Issue: 1 Linguagem: Inglês
10.1056/nejmoa1903307
ISSN1533-4406
AutoresKim N., Neeraj Agarwal, Anders Bjartell, Byung Ha Chung, Andrea Juliana Pereira de Santana Gomes, Robert Given, Álvaro Juárez Soto, Axel S. Merseburger, Mustafa Özgüroğlu, Hirotsugu Uemura, Dingwei Ye, Kris Deprince, Vahid Naini, Jinhui Li, Shinta Cheng, Margaret K. Yu, Ke Zhang, Julie S. Larsen, Sharon McCarthy, Simon Chowdhury,
Tópico(s)Cancer, Lipids, and Metabolism
ResumoApalutamide is an inhibitor of the ligand-binding domain of the androgen receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would prolong radiographic progression–free survival and overall survival as compared with placebo plus ADT among patients with metastatic, castration-sensitive prostate cancer has not been determined.
Referência(s)